TY - JOUR
T1 - Randomized trial of endobronchial ultrasound-guided transbronchial needle aspiration with and without rapid on-site evaluation for lung cancer genotyping
AU - Trisolini, Rocco
AU - Cancellieri, Alessandra
AU - Tinelli, Carmine
AU - De Biase, Dario
AU - Valentini, Ilaria
AU - Casadei, Gianpiero
AU - Paioli, Daniela
AU - Ferrari, Franco
AU - Gordini, Giovanni
AU - Patelli, Marco
AU - Tallini, Giovanni
PY - 2015/12/1
Y1 - 2015/12/1
N2 - BACKGROUND: Experts and scientifi c society guidelines recommend that rapid on-site evaluation (ROSE) be used with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to optimize lung cancer genotyping, but no comparative trial has been carried out to confi rm and quantify its usefulness. METHODS: To assess the influence of ROSE on the yield of EBUS-TBNA for a multigene molecular analysis of lung cancer samples, consecutive patients with suspected or known advanced lung cancer were randomized to undergo EBUS-TBNA without ROSE (EBUS arm) or with ROSE (ROSE arm). Th e primary end point was the rate of the successful accomplishment of the institution's clinical protocol for molecular profi ling of nonsquamous non-small cell lung cancer (EGFR and KRAS testing, followed by ALK testing for tumors with EGFR and KRAS wild-type status). RESULTS: Complete genotyping was achieved in 108 of 126 patients (85.7%) (90.8% in the ROSE arm vs 80.3% in the EBUS arm, P
AB - BACKGROUND: Experts and scientifi c society guidelines recommend that rapid on-site evaluation (ROSE) be used with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to optimize lung cancer genotyping, but no comparative trial has been carried out to confi rm and quantify its usefulness. METHODS: To assess the influence of ROSE on the yield of EBUS-TBNA for a multigene molecular analysis of lung cancer samples, consecutive patients with suspected or known advanced lung cancer were randomized to undergo EBUS-TBNA without ROSE (EBUS arm) or with ROSE (ROSE arm). Th e primary end point was the rate of the successful accomplishment of the institution's clinical protocol for molecular profi ling of nonsquamous non-small cell lung cancer (EGFR and KRAS testing, followed by ALK testing for tumors with EGFR and KRAS wild-type status). RESULTS: Complete genotyping was achieved in 108 of 126 patients (85.7%) (90.8% in the ROSE arm vs 80.3% in the EBUS arm, P
UR - http://www.scopus.com/inward/record.url?scp=84947481457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947481457&partnerID=8YFLogxK
U2 - 10.1378/chest.15-0583
DO - 10.1378/chest.15-0583
M3 - Article
C2 - 26158441
AN - SCOPUS:84947481457
VL - 148
SP - 1430
EP - 1437
JO - Chest
JF - Chest
SN - 0012-3692
IS - 6
ER -